Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study (EVOLVE-2)

I5Q-MC-CGAH -

The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with episodic migraine.

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Migraines
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
Yes
Enrollment Goal
986
Trial Dates
Dec 4, 2015 - Oct 5, 2018
How long will I be in the trial?
Your participation could last up to 12 months and include 14 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.